Aims: Glucagon receptor (GCGR) blockers are being investigated as potential therapeutics for type 1 and type 2 diabetes. Here we report the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of REGN1193, a fully human glucagon receptor blocking monoclonal antibody from a first-in-human healthy volunteer randomized double-blinded trial.
postprandial hyperglycaemia in people with type 2 diabetes (T2D), glucagon and the glucagon receptor have been investigated as potential targets for diabetes control. 6 Clinical trials with small molecule glucagon receptor antagonists in patients with T2D treated for up to 24 weeks have demonstrated a significant decrease in fasting glucose, postprandial glucose and HbA1c, without significant hypoglycaemia. [7] [8] [9] [10] Reversible increases in LDL-cholesterol and elevated serum hepatic aminotransferases levels have also been reported. 7, 9, 11 Modest increases in systolic and diastolic blood pressure (1.3-2.3 mm Hg) measured by 24-hour ambulatory blood pressure monitoring have recently been reported in patients with T2 diabetes after 6 weeks of treatment with a small molecule GCGR blocker. 9 We developed REGN1193, a human monoclonal GCGR-blocking antibody as a potential therapeutic for diabetes to determine if the safety and efficacy profile could be improved compared with small molecule glucagon receptor blockers. Preclinical studies with REGN1193
in diabetic monkeys provided evidence of a rapid glucose-lowering effect, but no increase in LDL-C or liver enzymes after single doses of 5 and 20 mg/kg. 12 Thus, the current phase 1 study (NCT01933763)
was conducted as part of a full development programme.
In this single-dose healthy volunteer study, the main objective was to assess the safety and tolerability profile of REGN1193. We also sought to determine the PK/PD profile of REGN1193 and to assess if the adverse laboratory effects reported with small molecule GCGR antagonists, ie, increases in hepatic aminotransferases
and LDL-C, were specific to small molecule GCGR antagonists.
| METHODS
This single-centre, phase I, single ascending dose, randomized, double-blinded study was conducted at Covance Clinical Research Unit in Dallas, TX, and sponsored by Regeneron Pharmaceuticals Inc., Tarrytown, NY. All patients provided written informed consent, and the study was conducted in accordance with the International Conference on Harmonization Good Clinical Practice guidelines and all applicable local regulatory requirements and laws.
| Patient eligibility
Eligible subjects were healthy men and women, 18 to 45 years of age during and for up to 3 months after participation in the study. Female subjects were screened for gynaecological cancers as recommended by the American Cancer Society. Other inclusion criteria were HbA1c
≤5.5%, fasting plasma glucose >70 and ≤110 mg/dL, systolic blood pressure between 90 and 140 mm Hg, diastolic blood pressure between 60 and 90 mm Hg, heart rate between 45 and 90 bpm, and clinically normal standard 12-lead electrocardiogram (ECG).
Exclusion criteria were any clinical abnormalities or significant concomitant illnesses that would preclude subjects from safely completing the study, and more specifically, a history of high blood pressure, abnormal fasting blood glucose or diabetes, unprovoked sweating, palpitations, frequent nausea, panic attacks, insulinoma, glucagonoma, pheochromocytoma, hypersensitivity to glucagon or lactose, adrenal hormone disorder, hypoglycaemia, renal hormone disorder, autonomic nervous system dysfunction, a hypersensitivity reaction to doxycycline or similar compound, malignancy (including carcinoma in situ) and family history of any type of multiple endocrine neoplasia (MEN) or any other genetic cancer predisposition.
Also exclusionary were fasting triglyceride concentrations >300 mg/ dL, catecholamine levels >2× the upper limit of normal (ULN) in a 24-hour urine test and blood donation of any volume within 1 month prior to administration of study drug.
| Antibody properties
REGN1193, derived using Regeneron's Velocimmune technology platform, 13 is a fully human monoclonal antibody that has a human IgG4 constant region with a stabilizing mutation in the hinge region (serine to proline in position 108 in accession P01861) to minimize half-antibody formation. REGN1193 demonstrates high affinity binding to mouse, rat, monkey and human GCGR and inhibits glucagon signaling through human GCGR in the picomolar range (EC 50 of 68 pM, using a cell-based reporter assay). 12 
| Study design and treatment
The study was a randomized, single-dose, placebo-controlled, doubleblinded design in 4 sequential ascending dose cohorts of 12 subjects enrolled at the following REGN1193 dose levels: 0.05, 0.1, 0.3 and 0.6 mg per kilogram of body weight. Dose rationale was based on glucose-lowering efficacy, toxicology and PK in preclinical animal models. The study drug was administered by IV infusion over 30 minutes. The REGN1193 drug product was supplied as a lyophilized powder in a 20 mL glass vial for IV administration.
The study design consisted of a screening period (day −28 to day −3) and a treatment and observation period (day 1 [baseline] to day 106) (Figure 1 ). All subjects were randomly assigned in a 3:1 ratio to receive either REGN1193 or placebo on day 1. Dose escalation cohorts consisted of two randomly assigned groups: Group A subjects (n = 4) did not undergo glucagon stimulation tests and group B subjects (n = 8) underwent glucagon stimulation tests on day −1 (~24 hours prior to study drug administration), day 3, day 8, day 15 and day 22.
Subjects in group A were admitted to the clinic on day −1 and subjects in group B on day −2; all subjects were discharged from the clinic after the day 4 safety assessments were completed. Subjects in the ascending dose cohorts were observed for at least 15 days after receiving REGN1193 before opening enrollment in the next dose cohort.
Dose escalation was discontinued at the 0.6 mg/kg dose level because that dose level inhibited ≥50% of the mean percent change in glucose in response to stimulation with glucagon on study day An additional cohort consisting of eight subjects was enrolled after the dose escalation portion of the study was completed to assess time to the onset of action of REGN1193 at the 0.3 mg/kg dose level. Subjects in this cohort underwent glucagon stimulation tests on day −1 (~24 hours prior to study drug administration), day 1 (~6 hours after study drug administration), and day 8. were collected from the timing of signing the informed consent through study day 106. All AEs reported in this study were coded using the Medical Dictionary for Regulatory Activities (MedDRA) version 16.1.
Subjects had periodic blood glucose monitoring and recording from the time of entry to the clinic until discharge from the clinic.
Testing was performed every 2 hours overnight (until the morning of day 4). During the daytime, testing was performed whenever indicated by subject signs or symptoms. Hypoglycaemia was defined as a blood glucose level <70 mg/dL (measured by venipuncture) accompanied by symptoms assessed to be due to hypoglycaemia. Any blood glucose measurement of <70 mg/dL was confirmed by a plasma glucose sample. Blood chemistries, lipid panels, haematology, pregnancy tests, and urine analyses were performed at Medpace Central Labs LLC (Cincinnati, Ohio). Additional blood samples were collected for assessment of endocrine hormones and other potential PD biomarkers as described below.
| Glucagon stimulation test

| Pharmacokinetic analysis
Blood samples for analysis of functional (ie, free and partially bound)
REGN1193 concentration in serum were collected on day 1 at pre- 
| Immunogenicity
Blood samples for analysis of anti-REGN1193 antibodies were collected prior to treatment on day 1, days 15, 29, 64, 85 and 106 (end Subjects in group A were admitted to the clinic on day −1 and subjects in group B on day −2. All subjects were discharged on day 4 of study), or at the time of early termination. Anti-REGN1193 antibodies (anti-drug antibodies; ADA) were assessed using an electrochemiluminescence bridging immunoassay. The minimal detectable titre was 30. Anti-drug antibody status (positive or negative) and titre category were reported (Glossary S1).
| Pharmacodynamic biomarker analysis
As subjects in group B received serial glucagon stimulation tests, the 
| Pharmacodynamic efficacy analysis
The 
| Pharmacokinetic-pharmacodynamic (PK-PD) analysis
The relationship between functional REGN1193 concentration and 3 | RESULTS
| Patient characteristics and disposition
In total, 342 subjects were screened, 56 of whom were enrolled in the study (16 and 40 subjects in groups A and B, respectively)
between August 2013 and September 2014. Screen failures were due primarily to subjects not meeting inclusion criteria related to HbA1c values, BMI and vital signs. Demographics and baseline characteristics of the subjects are provided in Table 1 .
| Pharmacokinetic (PK) profile
Evaluation of the functional REGN1193 concentration-time profiles in serum suggests two-compartment disposition and marked nonlinearity, consistent with target-mediated clearance (Figure 2 ). Mean clearance of functional REGN1193 was markedly dose dependent, declining from 272 mL/d/kg at 0.05 mg/kg to about 5 mL/d/kg at 0.6 mg/kg (see Table 2 ). Due to the nonlinearity in clearance, half-life estimates of functional REGN1193 in serum were dose and concentration-dependent, ranging from 0.5 to~4 days. As expected, administration of glucagon IV (0.8 mg) to subjects in group B (prior to treatment with REGN1193 or placebo) resulted in an increase in plasma glucose levels. Although the glucose levels were periodically measured for 240 minutes post-stimulation with glucagon, the efficacy analysis was focused on the first 90 minutes, Abbreviations: CL, clearance; C max , maximum concentration; N, number of subjects; SD, standard deviation; t 1/2 , half-life; V ss , steady-state volume of distribution.
| Pharmacodynamic (PD) effects
which encompassed the peak glucose levels and the return to prestimulation levels. No differences were seen at baseline for any of the cohorts on day −1. On day 3, a significant reduction in the mean glucose AUC and the mean peak glucose induced by glucagon stimulation was observed in subjects treated with 0.1, 0.3 and 0.6 mg/kg REGN1193 compared with placebo, while no effect was observed in subjects treated with 0.05 mg/kg REGN1193. By day 8, the inhibitory effect of 0.1 mg/kg REGN1193 was no longer evident. In contrast, the effect of the 0. 1 2 3 4 8 11 15 22 29 43 64 85 106 -1 1 2 3 4 8 11 15 22 29 43 64 85 106 -1 1 2 3 4 8 11 15 22 29 43 64 85 106 Day 
| PK-PD analysis
Time-dependent pharmacokinetics-pharmocodynamics (PK/PD) of functional REGN1193 in serum versus mean % change in AUC 0-90 minutes glucose in group B subjects (with glucagon stimulation) in the 0.3 and 0.6 mg/kg dose cohorts is shown in Figure 5A . A temporal fast response was observed after study drug IV administration. With increasing dose levels from 0.3 to 0.6 mg/kg, further glucose reduction was achieved and the duration of inhibition was prolonged.
The sigmoid E max model showed that glucose AUC declined monotonically with increasing functional REGN1193 concentration, reaching a maximum effect of~90% glucose reduction ( Figure S1 ). At a single dose of 0.6 mg/kg, at least 80% reduction was maintained for about 2 weeks before returning to its baseline ( Figure 5A ). In addition, the IC 50 value of REGN1193 was estimated to be 0.422 AE 0.066 mg/L.
Time-dependent PK/PD of functional REGN1193 in serum versus glucagon, GLP-1 and GLP-2 in group A subjects (without glucagon stimulation) in 0.3 and 0.6 mg/kg dose cohorts is shown in Figure 5B to D. A temporal fast on and slow off response was observed for each of the proglucagon products.
| Safety
All 56 subjects received a single dose of REGN1193 or placebo (42 and 14 subjects, respectively). Most subjects (92.9%) completed the study. Four subjects prematurely withdrew from the study, including two in the placebo group who were lost to follow-up, one in the 0.1 mg/kg group who was noncompliant with the protocol, and one in the 0.6 mg/kg group who withdrew consent due to change in work schedule that conflicted with study visits (Table S1 ).
In total, 36/56 subjects (64.3%) experienced at least 1 treatment emergent adverse event (TEAE) during the study. The overall TEAE profile was similar between treatment groups (57.1% and 66.7% subjects in the placebo and in the combined REGN1193 treatment groups, respectively) ( Table S1 ). No differences were observed in frequency of TEAEs among treatment cohorts. No infusion or injection site reactions were reported. One male subject with baseline bradycardia in the 0.6 mg/kg REGN1193 cohort developed an accelerated idioventricular rhythm on day 1 that resolved spontaneously on day 2. The diagnosis was confirmed by two independent cardiologists and was concluded to be of no clinical significance.
Symptomatic hypoglycaemic events were not reported and the observed frequency of asymptomatic hypoglycaemic events was infrequent and similar in the placebo and REGN1193 treatment groups (Table 3 ). There were no clinically meaningful changes in vital signs and laboratory tests by REGN1193. No subject treated with REGN1193 had alanine transaminase (ALT) levels above 3× the ULN.
One subject had aspartate transaminase (AST) >3× but <5× the ULN The most consistent adverse finding in clinical trials of glucagon receptor blockers has been a mild increase in ALT and AST without clinical symptoms or signs that resolved upon discontinuation of the agent. 7, 9, 16, 22, 23 However, there has been a report of a single patient with a homozygous inactivating mutation (P86S) in the glucagon receptor, who had normal ALT and AST from 64.7 to 66.9 years of age. 24, 25 As we observed similar increases in ALT and AST with our monoclonal antibody, the findings cannot be attributed to an offtarget small molecule effect. In addition, we observed these changes in healthy volunteers who are unlikely to have occult liver disease or hepatic steatosis. The recent publication of Lilly's small molecule glucagon receptor blocker (LY2409021) reported in patients with T2D
that there was an increase in hepatic fat fraction (3.7%) after 6 months of treatment that was significantly higher than placebo and sitagliptin. 26 Fourteen percent of patients on LY2409021 had a 10% or higher increase in hepatic fat. The increase in hepatic fat was associated with an increase in aminotransferases. Studies in large numbers of patients exposed to this class of agents for extended periods of time will need to be conducted to determine the potential consequences of the increase in hepatic aminotransferases. In conclusion, we demonstrated that REGN1193, a GCGRblocking monoclonal antibody, has a safety, tolerability and PK/PD profile suitable for further clinical development. The occurrence of transient elevations in serum hepatic aminotransferases observed here and reported with several small molecule glucagon receptor antagonists suggests an on-target effect of glucagon receptor blockade. The underlying mechanism is not known.
